Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 25 Jun 2019 |
| Major Shareholder Announcement | 25 Jun 2019 |
| Major Shareholder Announcement | 19 Jun 2019 |
| Major Shareholder Announcement | 19 Jun 2019 |
| Genmab A/S has published its Articles of Association | 13 Jun 2019 |
| Genmab Signs Agreement with Janssen for Next-Generation CD38 Antibody, HexaBody®-CD38 | 11 Jun 2019 |